Loading...
Market
Story
Ro Partners with Eli Lilly to Offer Lower-Priced Zepbound Vials with Cash-Pay Option
Dec 11, 2024, 01:42 PM
Telehealth company Ro has partnered with pharmaceutical giant Eli Lilly to expand access to Zepbound, a weight-loss drug containing tirzepatide. The partnership will enable Ro to offer lower-priced, single-dose vials of Zepbound through LillyDirect, Eli Lilly's self-pay pharmacy channel. Ro patients with on-label prescriptions will have access to the drug starting Wednesday, with a cash-pay option available. This collaboration comes amid ongoing shortages of semaglutide-based drugs, such as Ozempic, and questions about the future of compounded GLP-1 treatments. The announcement has impacted the stock performance of Hims & Hers Health, Inc. (HIMS), a company that sells compounded semaglutide, with shares falling 3.8% pre-market.
View original story
Similar markets
None • 33%
1-3 • 33%
More than 3 • 34%
Arrests made • 25%
No arrests but legal actions initiated • 25%
No legal actions taken • 25%
ZeroSevenGroup disbands • 25%
X Corp involved • 25%
Meta involved • 25%
Google involved • 25%
Other companies involved • 25%
Approved in US only • 33%
Approved in US and one other major market • 33%
Approved in US and multiple other major markets • 33%
Roche wins • 25%
Stanford and Foresight win • 25%
Settlement reached • 25%
Case dismissed • 25%